Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Enanta Pharmaceuticals (ENTA) over the last 12 years, with Q4 2025 value amounting to 0.75%.

  • Enanta Pharmaceuticals' Return on Invested Capital rose 1500.0% to 0.75% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.75%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 0.86% for FY2025, which is 1700.0% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Return on Invested Capital of 0.75% as of Q4 2025, which was up 1500.0% from 1.16% recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Return on Invested Capital registered a high of 0.21% during Q1 2021, and its lowest value of 1.16% during Q3 2025.
  • Moreover, its 5-year median value for Return on Invested Capital was 0.58% (2023), whereas its average is 0.6%.
  • Over the last 5 years, Enanta Pharmaceuticals' Return on Invested Capital had its largest YoY gain of 1500bps in 2025, and its largest YoY loss of -3300bps in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.3% in 2021, then plummeted by -33bps to 0.4% in 2022, then plummeted by -79bps to 0.71% in 2023, then dropped by -28bps to 0.9% in 2024, then rose by 17bps to 0.75% in 2025.
  • Its last three reported values are 0.75% in Q4 2025, 1.16% for Q3 2025, and 1.09% during Q2 2025.